Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib.

Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib.

Item
http://www.wikidata.org/entity/Q44902045
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro.Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall?Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity.Population pharmacokinetics of mycophenolic acid and its glucuronide metabolite in lung transplant recipients with and without cystic fibrosis.Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro.The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors.Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO-5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females.Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma.A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).
P2860

Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib.

Item
http://www.wikidata.org/entity/Q44902045
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Population pharmacokinetic/pha ...... edule selection for dovitinib.
@en
Population pharmacokinetic/pha ...... edule selection for dovitinib.
@nl
type
label
Population pharmacokinetic/pha ...... edule selection for dovitinib.
@en
Population pharmacokinetic/pha ...... edule selection for dovitinib.
@nl
prefLabel
Population pharmacokinetic/pha ...... edule selection for dovitinib.
@en
Population pharmacokinetic/pha ...... edule selection for dovitinib.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Population pharmacokinetic/pha ...... edule selection for dovitinib.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698